All nine members of the committee unanimously voted to recommend Moderna's new mRNA influenza vaccine for adults 50 and over.

MASSACHUSETTS - Advisers to the US Food and Drug Administration on June 18 backed approval of Moderna’s flu vaccine for adults aged 50 and older, saying its benefits outweigh the risks, boosting the ...

A Food and Drug Administration advisory panel on Thursday recommended the approval of Moderna’s mRNA-based flu shot for older adults.

Older adults who face the highest rates of flu hospitalization moved one step closer to a new vaccine option on June 18, 2026, when a federal advisory panel unanimously backed Moderna’s mRNA-based ...

VRBPAC endorsed mRNA-1010 for adults 50-64 and ≥65 years, unanimously concluding benefits outweighed risks, supporting a late-stage regulatory path toward potential first mRNA seasonal influenza ...

Moderna stock gains 3.5% after FDA advisory panel votes 9-0 that mFlusiva's benefits outweigh risks in influenza prevention in older adults, ahead of an Aug. 5 decision.

Moderna's mRNA flu vaccine could be approved by August, but federal policy and a nonfunctional advisory committee threaten ...

Independent advisors for the Food and Drug Administration on Friday voted 9–0 in support of approving Moderna’s seasonal mRNA flu vaccine, which a Trump appointee at the agency initially tried to ...

WASHINGTON — U.S. health advisers are debating a new kind of flu vaccine Thursday, the first made with the same mRNA technology that was key to ending the COVID-19 pandemic. Moderna is seeking Food ...

Investors should note that in February, the FDA issued a refusal-to-file letter regarding Moderna’s influenza vaccine, citing the choice of a standard-dose seasonal influenza vaccine as the sole ...